霍奇金淋巴瘤，2015年第2版。
Hodgkin lymphoma, version 2.2015.
作者信息
Hoppe Richard T, Advani Ranjana H, Ai Weiyun Z, Ambinder Richard F, Aoun Patricia, Bello Celeste M, Benitez Cecil M, Bierman Philip J, Blum Kristie A, Chen Robert, Dabaja Bouthaina, Forero Andres, Gordon Leo I, Hernandez-Ilizaliturri Francisco J, Hochberg Ephraim P, Huang Jiayi, Johnston Patrick B, Khan Nadia, Maloney David G, Mauch Peter M, Metzger Monika, Moore Joseph O, Morgan David, Moskowitz Craig H, Mulroney Carolyn, Poppe Matthew, Rabinovitch Rachel, Seropian Stuart, Tsien Christina, Winter Jane N, Yahalom Joachim, Burns Jennifer L, Sundar Hema
出版信息
J Natl Compr Canc Netw. 2015 May;13(5):554-86. doi: 10.6004/jnccn.2015.0075.
Abstract
Hodgkin lymphoma (HL) is an uncommon malignancy involving lymph nodes and the lymphatic system. Classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma are the 2 main types of HL. CHL accounts for most HL diagnosed in the Western countries. Chemotherapy or combined modality therapy, followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale), is the standard initial treatment for patients with newly diagnosed CHL. Brentuximab vedotin, a CD30-directed antibody-drug conjugate, has produced encouraging results in the treatment of relapsed or refractory disease. The potential long-term effects of treatment remain an important consideration, and long-term follow-up is essential after completion of treatment.
摘要
霍奇金淋巴瘤（HL）是一种累及淋巴结和淋巴系统的罕见恶性肿瘤。经典型霍奇金淋巴瘤（CHL）和结节性淋巴细胞为主型霍奇金淋巴瘤是HL的两种主要类型。CHL占西方国家诊断出的大多数HL病例。化疗或综合治疗，随后用PET/CT重新分期，以使用多维尔标准（5分制）评估治疗反应，是新诊断CHL患者的标准初始治疗方法。靶向CD30的抗体药物偶联物brentuximab vedotin在复发或难治性疾病的治疗中取得了令人鼓舞的结果。治疗的潜在长期影响仍然是一个重要的考虑因素，治疗完成后长期随访至关重要。
相似文献
1
Hodgkin lymphoma, version 2.2015.霍奇金淋巴瘤，2015年第2版。
J Natl Compr Canc Netw. 2015 May;13(5):554-86. doi: 10.6004/jnccn.2015.0075.
2
Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.霍奇金淋巴瘤 1.2017 年版，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2017 May;15(5):608-638. doi: 10.6004/jnccn.2017.0064.
3
A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.在干细胞移植前后，对经过大量治疗的难治性或复发性儿童霍奇金淋巴瘤患者采用维布妥昔单抗进行靶向挽救治疗。
Turk J Pediatr. 2019;61(5):671-676. doi: 10.24953/turkjped.2019.05.005.
4
18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.18-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描用于评估复发难治性霍奇金淋巴瘤患者对本妥昔单抗治疗的反应
Leuk Lymphoma. 2014 Apr;55(4):811-6. doi: 10.3109/10428194.2013.819575. Epub 2013 Jul 29.
5
The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.欧洲药品管理局对用于治疗复发或难治性CD30+霍奇金淋巴瘤或系统性间变性大细胞淋巴瘤成年患者的本妥昔单抗（安适利）的审评：人用药品委员会科学评估总结
Oncologist. 2016 Jan;21(1):102-9. doi: 10.1634/theoncologist.2015-0276. Epub 2015 Nov 30.
6
Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management.霍奇金淋巴瘤：2016 年诊断、风险分层和治疗更新。
Am J Hematol. 2016 Jun;91(4):434-42. doi: 10.1002/ajh.24272.
7
Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management.霍奇金淋巴瘤：2020 年诊断、风险分层和治疗的更新。
Am J Hematol. 2020 Aug;95(8):978-989. doi: 10.1002/ajh.25856. Epub 2020 Jun 8.
8
SEOM clinical guidelines for the treatment of Hodgkin's lymphoma.霍奇金淋巴瘤治疗的SEOM临床指南。
Clin Transl Oncol. 2015 Dec;17(12):1005-13. doi: 10.1007/s12094-015-1429-1. Epub 2015 Oct 26.
9
F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.18F-FDG-PET 预测复发和难治性霍奇金淋巴瘤患者接受全身淋巴照射和自体造血干细胞移植的预后。
Br J Haematol. 2014 Jun;165(6):793-800. doi: 10.1111/bjh.12824. Epub 2014 Mar 15.
10
Hodgkin Lymphoma: Diagnosis and Treatment.霍奇金淋巴瘤：诊断与治疗
Mayo Clin Proc. 2015 Nov;90(11):1574-83. doi: 10.1016/j.mayocp.2015.07.005.
引用本文的文献
1
The Role of Artificial Intelligence and Radiomics in the Management of Lymphomas by PET/CT: The Clairvoyance in Clinic.人工智能和影像组学在淋巴瘤PET/CT管理中的作用：临床中的透视眼
Cancer Manag Res. 2025 Jul 19;17:1457-1475. doi: 10.2147/CMAR.S529589. eCollection 2025.
2
Long-Axial Field-of-View PET Imaging in Patients with Lymphoma: Challenges and Opportunities.淋巴瘤患者的长轴向视野 PET 成像：挑战与机遇。
PET Clin. 2024 Oct;19(4):495-504. doi: 10.1016/j.cpet.2024.05.005. Epub 2024 Jul 4.
3
Intramuscular lymphoma: uncommon presentation of Hodgkin's disease.肌肉内淋巴瘤：霍奇金病的不常见表现。
BMJ Case Rep. 2020 Aug 26;13(8):e229826. doi: 10.1136/bcr-2019-229826.
4
Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort.与吉西他滨使用相关的血栓性微血管病：法国全国回顾性队列研究中的表现和结局。
Br J Clin Pharmacol. 2019 Feb;85(2):403-412. doi: 10.1111/bcp.13808. Epub 2018 Dec 18.
5
Long-Term Survival Rates of Patients with Stage III-IV Hodgkin Lymphoma According to Age, Sex, Race, and Socioeconomic Status, 1984-2013.1984-2013 年，根据年龄、性别、种族和社会经济地位，III-IV 期霍奇金淋巴瘤患者的长期生存率。
Oncologist. 2018 Nov;23(11):1328-1336. doi: 10.1634/theoncologist.2017-0541. Epub 2018 May 8.
6
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.本妥昔单抗维迪西妥单抗联合苯达莫司汀：复发或难治性霍奇金淋巴瘤的高效一线挽救治疗方案。
Blood. 2018 Jul 5;132(1):40-48. doi: 10.1182/blood-2017-11-815183. Epub 2018 Apr 27.
7
The role of FDG-PET in Hodgkin lymphoma.氟代脱氧葡萄糖正电子发射断层扫描（FDG-PET）在霍奇金淋巴瘤中的作用。
Contemp Oncol (Pozn). 2017;21(2):104-114. doi: 10.5114/wo.2017.68618. Epub 2017 Jun 30.
8
Importance of baseline PET/CT imaging on radiation field design and relapse rates in patients with Hodgkin lymphoma.基线PET/CT成像对霍奇金淋巴瘤患者放射野设计及复发率的重要性。
Adv Radiat Oncol. 2017 Jan 18;2(2):197-203. doi: 10.1016/j.adro.2017.01.006. eCollection 2017 Apr-Jun.
9
Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China.亚太地区血液肿瘤学实践：第六届国际血液系统恶性肿瘤会议（2015年中国北京，弥合差距）的亚太血液肿瘤学大会（APHCON）调查结果
Oncotarget. 2017 Jun 20;8(25):41620-41630. doi: 10.18632/oncotarget.15655.
10
Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis.候选基因关联研究蒽环类药物诱导的心脏毒性：系统评价和荟萃分析。
Sci Rep. 2017 Feb 27;7(1):39. doi: 10.1038/s41598-017-00075-1.
本文引用的文献
1
Cancer statistics, 2015.癌症统计数据，2015 年。
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.
2
Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.在一项关于复发或难治性霍奇金淋巴瘤的本妥昔单抗关键2期研究中实现持久缓解。
Blood. 2015 Feb 19;125(8):1236-43. doi: 10.1182/blood-2014-08-595801. Epub 2014 Dec 22.
3
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.影像学在淋巴瘤分期及疗效评估中的作用：恶性淋巴瘤国际会议影像工作组共识
J Clin Oncol. 2014 Sep 20;32(27):3048-58. doi: 10.1200/JCO.2013.53.5229.
4
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.霍奇金淋巴瘤和非霍奇金淋巴瘤初始评估、分期及反应评估的建议：卢加诺分类
J Clin Oncol. 2014 Sep 20;32(27):3059-68. doi: 10.1200/JCO.2013.54.8800.
5
ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial.ABVD（8 个周期）与 BEACOPP（4 个递增周期≥4 个基线：IPS 0-2）在 III-IV 期低危霍奇金淋巴瘤（LYSA H34 随机试验）中的最终结果。
Ann Oncol. 2014 Aug;25(8):1622-8. doi: 10.1093/annonc/mdu189. Epub 2014 May 14.
6
Active breathing control for patients receiving mediastinal radiation therapy for lymphoma: Impact on normal tissue dose.接受纵隔放射治疗的淋巴瘤患者的主动呼吸控制：对正常组织剂量的影响。
Pract Radiat Oncol. 2014 May-Jun;4(3):174-180. doi: 10.1016/j.prro.2013.07.015. Epub 2013 Sep 16.
7
Dosimetric advantages of a "butterfly" technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin's lymphoma.“蝴蝶”技术在年轻女性纵隔霍奇金淋巴瘤患者调强放射治疗中的剂量学优势
Radiat Oncol. 2014 Apr 15;9:94. doi: 10.1186/1748-717X-9-94.
8
Changes in breast cancer risk associated with different volumes, doses, and techniques in female Hodgkin lymphoma patients treated with supra-diaphragmatic radiation therapy.膈上放射治疗的女性霍奇金淋巴瘤患者中，不同容积、剂量和技术与乳腺癌风险变化的相关性。
Pract Radiat Oncol. 2013 Jul-Sep;3(3):216-222. doi: 10.1016/j.prro.2012.12.006. Epub 2013 Feb 1.
9
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale.使用多维尔五分法的解读标准证实了中期正电子发射断层扫描对霍奇金淋巴瘤治疗结果的预测作用。
Haematologica. 2014 Jun;99(6):1107-13. doi: 10.3324/haematol.2013.103218. Epub 2014 Mar 21.
10
Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.早期正电子发射断层扫描阴性 I/II 期霍奇金淋巴瘤中省略放疗与早期复发风险增加相关：前瞻性随机 EORTC/LYSA/FIL H10 试验的中期分析的临床结果。
J Clin Oncol. 2014 Apr 20;32(12):1188-94. doi: 10.1200/JCO.2013.51.9298. Epub 2014 Mar 17.
Zotero 插件